非酒精性脂肪性肝炎患者晚期肝纤维化血清检测的验证
该研究基于396例非酒精性脂肪性肝病(NAFLD)患者肝活检当日血清样本,利用α2巨球蛋白、透明质酸和TIMP1金属肽酶抑制剂1构建判别晚期纤维化(F3-F4)的算法,并在两个独立验证队列(共640例)中验证,训练队列AUROC为0.867,验证队列AUROC为0.856,阴性预测值范围为92.5%至94.7%。
要点
- 基于A2M、HA和TIMP1的血清算法在训练队列中判别晚期纤维化的AUROC为0.867。
- 验证队列(n=640)中预定 cutoff 17 下敏感度79.7%、特异度75.7%、AUROC 0.856。
- 验证队列中阴性预测值范围为92.5%至94.7%,算法可无创评估晚期纤维化风险。
核心结论
- 基于血清生物标志物水平的算法可区分NAFLD患者中的晚期纤维化与轻中度纤维化,AUROC约0.86,并在两个独立的活检证实NAFLD患者组中得到验证。
- 该算法可无创用于确定NAFLD患者晚期纤维化的风险。
研究设计与样本
- 回顾性分析2007年至2017年肝活检当日采集的396例不同纤维化分期(F0-F4)NAFLD患者血清样本(训练队列1),检测A2M、HA和TIMP1浓度并构建判别晚期纤维化(F3-F4,占队列24.1%)与轻中度纤维化(F0-F2,占队列79.5%)的算法。
- 验证算法使用同一时期和地点另外396例患者的血清样本(验证队列1),以及2011年至2017年在另一地点评估的244例NAFLD患者(队列2),后者肝活检中位间隔11天。
主要发现
- 训练队列1中,算法在 cutoff 评分17时判别晚期纤维化 vs 轻中度纤维化的AUROC为0.867(95% CI 0.827-0.907),敏感度84.8%(95% CI 75.5%-91.0%),特异度72.3%(95% CI 66.9%-77.3%)。
- 合并验证队列1和2(n=640)中,预定 cutoff 评分17时AUROC为0.856(95% CI 0.820-0.892),敏感度79.7%(95% CI 71.9%-86.2%),特异度75.7%(95% CI 71.8%-79.4%)。
- 验证队列中阴性预测值范围为92.5%至94.7%。
- 算法正确分类90.0%的F0样本、75.0%的F1样本、77.4%的F3样本和94.4%的F4样本。
关键数值与推荐
- 训练队列1中 cutoff 评分17时AUROC 0.867(95% CI 0.827-0.907),敏感度84.8%(95% CI 75.5%-91.0%),特异度72.3%(95% CI 66.9%-77.3%)。
- 合并验证队列1和2(n=640)中预定 cutoff 评分17时AUROC 0.856(95% CI 0.820-0.892),敏感度79.7%(95% CI 71.9%-86.2%),特异度75.7%(95% CI 71.8%-79.4%)。
- 验证队列中阴性预测值范围为92.5%至94.7%。
临床怎么用
- 作者认为该算法可无创用于确定NAFLD患者晚期纤维化的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We analyzed markers of fibrosis in serum samples from patients with nonalcoholic fatty liver disease (NAFLD), assessed by liver biopsy. We used serum levels of markers to develop an algorithm to discriminate patients with advanced fibrosis from those with mild or moderate fibrosis and validated its performance in 2 independent cohorts of patients with NAFLD. METHODS: We performed a retrospective analysis of serum samples from 396 patients with NAFLD and different stages of fibrosis (F0-F4), collected from 2007 through 2017 on the day of liver biopsy (training cohort 1). We measured serum concentrations of alpha-2 macroglobulin (A2M), hyaluronic acid (HA), and TIMP metallopeptidase inhibitor 1 (TIMP1), and used measurements to develop an algorithm that could discriminate patients with NAFLD with advanced fibrosis (F3-F4; 24.1% of cohort) from those with mild or moderate fibrosis (F0-F2; 79.5% of cohort). We validated the algorithm using serum samples collected from a separate 396 patients from the same time period and location (validation cohort 1), as well as 244 patients with NAFLD evaluated at a separate location, from 2011 through 2017, within a median of 11 days of liver biopsy (cohort 2). RESULTS: The algorithm identified patients with advanced fibrosis vs mild or moderate fibrosis in training cohort 1 with an area under the receiver operating characteristic (AUROC) curve of 0.867 (95% CI, 0.827-0.907), 84.8% sensitivity (95% CI, 75.5%-91.0%), and 72.3% specificity (95% CI, 66.9%-77.3%), at a cutoff score of 17. The AUROC for the combined validation cohorts 1 and 2 (n=640) was 0.856 (95% CI, 0.820-0.892), identifying patients with 79.7% sensitivity (95% CI, 71.9%-86.2%) and 75.7% specificity (95% CI, 71.8%-79.4%) at the predetermined cutoff score of 17. The algorithm had negative predictive values that ranged from 92.5% to 94.7% in the validation cohorts; it correctly classified 90.0% of F0 samples, 75.0% of F1 samples, 77.4% of F3 samples, and 94.4% of F4 samples. CONCLUSION: We developed an algorithm that identifies patients with advanced fibrosis from those with mild to moderate fibrosis in patients with NAFLD with an AUROC value of approximately 0.86, based on levels of serum biomarkers. We validated the findings in 2 separate sets of patients with biopsy-proven NAFLD. The algorithm can be used non-invasively to determine risk of advanced fibrosis in patients with NAFLD.
引用
- Loomba R, Jain A, Diehl AM, et al. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2018. PMID: 30448594. doi:10.1016/j.cgh.2018.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。